GLP-1 Oral Tablets: FDA Clearance and What It Means for Plastic Surgery Patients

The landscape of weight management changed dramatically in early 2026. The FDA cleared Wegovy (semaglutide) 25mg tablets — the first oral GLP-1 receptor agonist approved specifically for chronic weight management — followed by Foundayo (orforglipron) tablets from Eli Lilly in April 2026. Both are administered as once-daily oral tablets, eliminating the need for weekly injections. For patients considering aesthetic and reconstructive surgery after significant weight loss, this is a pivotal development worth understanding.

What Are GLP-1 Oral Tablets?

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic a natural gut hormone that regulates appetite, slows gastric emptying, and improves glycemic control. Until recently, all FDA-approved GLP-1 therapies for weight management required subcutaneous injection. The new tablet formulations represent a major advance in patient convenience and adherence.

• Wegovy (semaglutide) tablets 25mg: Novo Nordisk. Approved December 2025 for weight management. The OASIS 4 trial demonstrated average weight loss of approximately 16.6% when patients remained on treatment. Indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and to reduce the risk of major adverse cardiovascular events.
• Foundayo (orforglipron) tablets: Eli Lilly. Approved April 2026 under the FDA's National Priority Voucher Program — the fastest approval of a new molecular entity since 2002. Indicated for chronic weight management and as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.

FDA-Cleared Indications

Both medications share core indications but differ in their diabetes labeling:

• Chronic weight management: Adults with BMI ≥30 (obesity) or BMI ≥27 (overweight) with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnoea).
• Cardiovascular risk reduction (Wegovy): Reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
• Glycemic control (Foundayo): Improving blood glucose control in adults with type 2 diabetes, alongside diet and exercise.

Key Trial Data at a Glance

• Wegovy oral tablets achieved mean weight loss of ~16.6% in the OASIS 4 trial (68 weeks), with ~14% in the intent-to-treat population.
• Foundayo demonstrated significant weight reduction and HbA1c improvements in phase 3 trials, with the advantage of once-daily oral dosing without food-timing restrictions.
• Both drugs carry a boxed warning regarding thyroid C-cell tumour risk (based on rodent GLP-1 data) and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

What This Means for Plastic Surgery Patients

As a triple board-certified plastic surgeon with three decades of experience, I see a growing cohort of patients who have lost 15–25% of their body weight on GLP-1 therapy. The aesthetic consequences — the so-called "Ozempic face" and "Ozempic body" — are real:

• Skin laxity: Rapid fat loss outpaces skin retraction, leading to redundant tissue in the face, neck, abdomen, arms, and thighs.
• Volume deflation: Loss of deep and superficial fat compartments creates hollow temples, deflated cheeks, and gaunt lower facial features.
• Breast ptosis: Significant weight loss accelerates breast drooping, often requiring combined lift and augmentation or reduction.
• Body contour irregularities: Excess skin folds in the abdomen, back (bra rolls), and medial thighs become both an aesthetic and functional concern.

Timing Surgery After GLP-1 Weight Loss

The international consensus in aesthetic medicine recommends a stable weight plateau of at least 3–6 months before undertaking major body contouring procedures. This ensures:

• Accurate surgical planning and predictable tissue behaviour under anaesthesia.
• Reduced risk of postoperative nutritional deficiencies (common in rapid-weight-loss patients).
• Optimised skin elasticity assessment at the point of maximum retraction.
• Minimised risk of contour deformity if further weight loss occurs after surgery.

Procedures Most Requested After GLP-1 Therapy

In my Istanbul practice, the most common post-GLP-1 body contouring requests include:

• 360° lower body lift and extended abdominoplasty for abdominal and flank laxity.
• Arm lift (brachioplasty) and thigh lift for circumferential skin excess.
• Facial fat grafting and facelift (including the K Face Lift and EndoChor deep-plane techniques) to restore youthful volume and reposition descended tissues.
• Breast lift with augmentation (Twirl Internal Bra / Smart BRA) or breast reduction to redefine breast aesthetics.
• Advanced Safe BBL to redistribute residual fat and improve lower body proportions after massive weight loss.

Final Thoughts

Oral GLP-1 tablets are a breakthrough for millions struggling with obesity. But weight loss is only half the journey. The second half — restoring skin tightness, youthful contours, and body proportions — is where plastic surgery completes the transformation. If you are currently on or considering GLP-1 therapy and want to plan your aesthetic next steps, a consultation with an experienced body contouring surgeon is the logical next move.